title: Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues.
abstract: Immunohistochemical studies were performed to clarify the significance of the expression or overexpression of epidermal growth factor (EGF), EGF-receptor (EGFR), p53, v-erb B, ras p21 in 23 cases each of tubular adenoma and adenocarcinoma. The expression of EGF, EGFR, p53, v-erb B, and ras p21 in paraffin-embedded tissues, from 46 patients with colorectal tumors (adenoma: 23 cases; 14 mild dysplasia, six moderate dysplasia, three severe dysplasia, adenocarcinoma: 23 cases; 17 well differentiated, two moderately differentiated, three poorly differentiated, one mucinous carcinoma was analyzed immunohistochemically using anti-EGF, EGFR, p53, v-erb B and ras p21 antibodies. The EGF and ras p21 tended to express more strongly in carcinoma cases than in the adenoma cases, and in severe and moderate dysplasia than in mild dysplasia (EGF: stained positive in five adenomas [21.74%] and 17 adenocarcinomas [73.91%]; ras p21: stained positive in six adenomas [26.09%] and 14 adenocarcinomas [60.87%]. The EGFR stained positive in two adenomas (8.70%) and two adenocarcinomas (8.70%). The p53 and v-erb B showed positive staining only in the carcinoma cases (p53: stained positive in four cases [17.39%]; v-erb B: stained positive in eight cases [34.78%]). This study suggests that these factors seem to have some role in the progression of colon neoplasms. It suggests that genetic alteration is not always equal to the overexpression of protein products, but that it reflects them well, and that the staining makes some contribution to differential diagnosis in colorectal neoplasms.
authors.affiliation: First Department of Pathology, Kobe University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Y W
authors.initials: YW
authors.lastname: Widjono
authors.forename: K
authors.initials: K
authors.lastname: Ohta
authors.forename: K
authors.initials: K
authors.lastname: Hanioka
authors.forename: C
authors.initials: C
authors.lastname: Obayashi
authors.forename: K
authors.initials: K
authors.lastname: Itoh
authors.forename: Y
authors.initials: Y
authors.lastname: Imai
authors.forename: H
authors.initials: H
authors.lastname: Itoh
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology; D000236:Adenoma / Q000737:chemistry / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000473:pathology*; D004815:Epidermal Growth Factor / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009375:Neoplasms, Glandular and Epithelial / Q000737:chemistry* / Q000473:pathology*; D018739:Oncogene Proteins v-erbB; D011230:Precancerous Conditions / Q000737:chemistry / Q000473:pathology; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis; D015682:Retroviridae Proteins, Oncogenic / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D009363:Neoplasm Proteins; D018739:Oncogene Proteins v-erbB; D015682:Retroviridae Proteins, Oncogenic; D016159:Tumor Suppressor Protein p53; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)